Novo Nordisk A/S Q4 Earnings Call Highlights

Core Insights - The global GLP-1 market experienced over 30% growth in 2025, with Novo Nordisk's U.S. operations growing by 8% and international operations by 14% [1] - Novo Nordisk's obesity care sales surged from DKK 6 billion in 2019 to DKK 82 billion in 2025, expanding its reach to an additional 16 million people since 2019 [3] - The company reported a 10% sales growth and a 6% operating profit growth in 2025 at constant exchange rates, marking the end of strategic aspirations set in 2019 [4] Sales and Market Performance - International operations saw a 44% volume growth in GLP-1 products in 2025, maintaining a 62% volume market share [6] - U.S. GLP-1 diabetes care sales increased by 5% in 2025, driven by Ozempic uptake, with weekly prescriptions around 610,000 [7] - The Wegovy pill, launched in the U.S. on January 5, 2025, was characterized as a first-in-class oral GLP-1 for weight management, with early prescription levels reaching about 50,000 in the week ending January 23 [8][9] Product Launches and Pipeline - The Wegovy pill is available at over 70,000 retail pharmacies and through telehealth partners, with commercial coverage progressing through major insurers [9] - Injectable Wegovy sales in the U.S. increased by 16% in 2025, with approximately 230,000 weekly prescriptions noted [10] - The company is advancing its pipeline, with a Phase 3 readout for CagriSema showing superior A1c reduction and weight loss compared to semaglutide [12][13] Financial Outlook - The gross margin for 2025 fell to 81% from 84.7% in 2024, impacted by restructuring costs and amortization related to acquisitions [15] - For 2026, adjusted sales growth is expected to decline by 5% to 13%, attributed to lower realized prices and loss of exclusivity for semaglutide in certain markets [16] - Novo Nordisk anticipates free cash flow of DKK 35-45 billion in 2026 and plans a total dividend of DKK 11.70 for 2025, marking a 2.6% increase [17]